Growing public conversation on perimenopause sparks warnings over misinformation on symptoms and HRT

Perimenopause has entered the public spotlight as celebrities and clinicians discuss their experiences online, but experts are cautioning that increased attention has also brought a rise in misleading claims about treatments such as hormone replacement therapy. A Guardian podcast explores the concerns with clinicians and a science correspondent sets out the factual picture on symptoms, testing and care.

Perimenopause has become a prominent topic in public discourse, with high-profile figures and healthcare professionals sharing personal accounts and advice across social media and other platforms. While many advocates say the increased visibility is helping to reduce stigma and prompt conversations about midlife health, clinicians are reporting a parallel surge in confusion and inaccurate information.

Subheading: Experts raise alarm on treatment misinformation

On the Guardian podcast, Madeleine Finlay speaks with Dr Paula Briggs, a consultant in sexual and reproductive health, about why experts have sounded the alarm. According to the discussion, the concern centres on claims circulating about remedies and interventions, particularly around hormone replacement therapy (HRT), that may be misleading or unsupported by evidence.

Subheading: Clarifying facts on symptoms, tests and treatments

Science correspondent Nicola Davis contributes to the programme by outlining the established medical understanding of perimenopause, summarising what is known about typical symptoms, diagnostic approaches and therapeutic options. The segment is intended to help listeners separate reliable clinical guidance from unverified or anecdotal claims encountered online.

Subheading: Public awareness with caution

The podcast positions growing public awareness as broadly positive for women's health, while emphasising the need for accurate information and professional medical advice when considering treatment. Listeners are directed to the conversation with clinicians and the science correspondent for a clearer, evidence-based view of perimenopause, its management and the potential risks of misinformation.